Citius Oncology (CTOR) Preferred Stock Liabilities (2022 - 2024)

Citius Oncology (CTOR) has 3 years of Preferred Stock Liabilities data on file, last reported at $49.2 million in Q2 2024.

• On a quarterly basis, Preferred Stock Liabilities fell 29.16% year-over-year to $49.2 million in Q2 2024; TTM through Jun 2024 was $49.2 million, a 29.16% decrease from a year earlier, with the FY2023 full-year figure at $72.6 million, up 7.01% from the prior year.
• Preferred Stock Liabilities for Q2 2024 stood at $49.2 million, up from $48.3 million in the prior quarter.
• Over the last five years, Preferred Stock Liabilities for CTOR reached as high as $72.6 million in Q4 2023 and fell as low as $48.3 million in Q1 2024.
• Historically, Preferred Stock Liabilities has averaged $63.8 million across 3 years, with a median of $68.6 million in 2023.
• Across the five-year window, Preferred Stock Liabilities gained 7.01% in 2023 and slipped 29.54% in 2024, its largest moves.
• Year by year, Preferred Stock Liabilities stood at $67.8 million in 2022, then increased by 7.01% to $72.6 million in 2023, then tumbled by 32.26% to $49.2 million in 2024.
• Per Business Quant data, the three most recent Preferred Stock Liabilities figures were $49.2 million in Q2 2024, $48.3 million in Q1 2024, and $72.6 million in Q4 2023.